Tetra Bio-Pharma Announces PPP003 Program Update Following Type B Meeting With U.S. FDA
Proposed clinical development pathway confirmed by FDA Ottawa, Ontario, June 17, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-derived drug discovery and development…